PA-BOOMI
16.5.2023 16:01:30 CEST | Business Wire | Press release
BoomiTM, the intelligent connectivity and automation leader, today announced Boomi AI – a first-of-its-kind, simplified user experience that harnesses generative AI to connect and integrate applications, data, processes, people, and things across organizations – creating business outcomes faster than ever before.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230516005335/en/
Boomi Changes the Integration and Automation Game With Boomi AI (Graphic: Business Wire)
“The introduction of Boomi AI marks yet another milestone in our long history of pioneering innovation in the integration industry,” said Ed Macosky, Chief Product Officer at Boomi. “We pioneered the first low-code, cloud-native integration platform as a service (iPaaS) to disrupt the middleware market 20+ years ago. Then, over a decade ago, Boomi pioneered AI-assisted development with the launch of Boomi Suggest, which further disrupted the market. Now, we are taking our intelligent integration and automation platform to the next level by making it AI-first – enabling AI to responsibly build and complete integrations, and transform automation for our customers.”
In today’s constantly changing market, organizations are making substantial investments to modernize their digital operations. According to IDC, global spending on AI will increase by 26.9% in this next year alone. However, disconnected ecosystems make it difficult for IT teams to focus on strategic initiatives. Fragmented tools, applications, and data can cause confusion and coordination issues, as teams lack a centralized platform for integration, API management, orchestration, and automation, resulting in time spent on maintenance, not innovation.
Boomi’s AI engine is fueled by the company’s approximately 20,000 customers – the largest customer base among integration platform vendors. Boomi AI leverages anonymized metadata, patterns, and best practices from the 200 million integrations made with the Boomi platform to train the AI models to create high-quality integrations across various business processes and applications, such as data management, customer experience optimization, or supply chain processes.
“Boomi’s extensive knowledge base makes our AI engine far more advanced than the AI-assisted development tools available today. It also benefits users by continuously testing patterns to ensure optimal integration design and root out risks and errors early, enabling customers to achieve tremendous gains in efficiency, operational improvements, and other desirable business outcomes,” added Macosky.
With Boomi AI, organizations can:
Design Connections: Boomi AI can design integration processes, application programming interfaces, and master data models with built-in best practices from millions of successful use cases, through a quick command, like, “Connect my CRM and invoice systems.”
Optimize Operations: With Boomi AI’s actionable intelligent insights, users can solve problems proactively, facilitate predictive maintenance, automate updates, and allocate optimal resources to enable software to efficiently self-manage itself. These insights, like “A data attribute in Salesforce has changed. Would you like to apply it across your systems?” make previously menial tasks quick and easy.
Orchestrate Experiences: Boomi AI can interpret intent behind desired business outcomes to orchestrate processes across applications. It enhances decision-making, simplifies tasks, and improves engagement while providing audit history and prompts to confirm intent so that decisions and outcomes are always explainable, creating even greater synergies between IT and the business. With a simple prompt like “Automate invoice processing,” IT teams and business leaders can focus on what matters most.
Enable Responsible AI Development: Boomi’s AI algorithms are trained to avoid biases and unfairness with established ethical guidelines for the development and use of AI within the Boomi platform. These guidelines confirm that Boomi’s AI technology is used in a transparent and accountable manner, and that it does not violate any ethical principles or laws. Additionally, Boomi has achieved U.S. Federal Risk and Authorization Management Program (FedRAMP) Authorization Moderate, a government-wide program that provides a standardized approach to security assessment. Boomi AI does not store any customer-specific information of any kind.
“In today's fast-paced market, organizations need more powerful tools that enable them to outperform, and AI presents a potent new avenue to do this,” says Dion Hinchcliffe, VP and Principal Analyst of Constellation Research. “By embracing an important new AI-first approach, organizations can unlock new levels of efficiency, innovation, and competitive advantage, to immediately capture opportunity as well as ensure their business remains future-ready.”
As the pioneer of cloud-native integration platform as a service (iPaaS), Boomi celebrates a growing community of more than 100,000 members, and one of the largest arrays of global systems integrators (GSIs) in the iPaaS space. The company boasts a worldwide network of partners, including Accenture, Deloitte, SAP, and Snowflake; and works with the largest hyperscaler cloud service providers, including Amazon Web Services, Google, and Microsoft, among others.
Included on the Deloitte Technology Fast 500™ and Inc. 5000 lists as one of America’s fastest growing and most innovative technology companies, Boomi was recently named to Nucleus Research's list of “Hot Companies to Watch in 2023.” The company has also won numerous awards, including three International Stevie® Awards, for Company of the Year (two years in a row) and Product Innovation; the Gold Globee® Award in the Platform as a Service (PaaS) category; the Merit Award for Technology in the Cloud Services category; the Stratus Award as a Global Leader in Cloud Computing 2022; and received the prestigious 5-star rating in the CRN Partner Program Guide for two consecutive years.
Join the Boomi AI waitlist at boomi.ai.
Additional Resources
- Read more about accelerating outcomes with Boomi AI
- Learn more about the Boomi platform
- Explore the Boomiverse Community
- Follow Boomi on Twitter, LinkedIn, Facebook, and YouTube
About Boomi
Boomi aims to make the world a better place by connecting everyone to everything, anywhere. The pioneer of cloud-based integration platform as a service (iPaaS), and now a category-leading, global software as a service (SaaS) company, Boomi touts the largest customer base among integration platform vendors and a worldwide network of approximately 800 partners – including Accenture, Capgemini, Deloitte, SAP, and Snowflake. Global organizations turn to Boomi’s award-winning platform to discover, manage, and orchestrate data, while connecting applications, processes, and people for better, faster outcomes. For more information, visit http://www.boomi.com.
© 2023 Boomi, LP. Boomi, the ‘B’ logo, and Boomiverse are trademarks of Boomi, LP or its subsidiaries or affiliates. All rights reserved. Other names or marks may be the trademarks of their respective owners.
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230516005335/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Incyte Announces New Positive 54-Week Late-Breaking Data for Povorcitinib in Hidradenitis Suppurativa at the 2026 American Academy of Dermatology (AAD) Annual Meeting28.3.2026 20:00:00 CET | Press release
Phase 3 data from the STOP-HS program demonstrate povorcitinib’s substantial and durable clinical efficacy through Week 54 in patients with moderate to severe hidradenitis suppurativa (HS). Through Week 54, clinically meaningful and durable responses were observed across all groups in both STOP-HS1 and STOP-HS2, with up to 71.4% of patients achieving HiSCR50. Improvements in clinical responses across high stringent thresholds were observed, with up to 57% of participants achieving HiSCR75 and up to 29% of participants achieving HiSCR100. Povorcitinib treatment led to consistent reductions across key inflammatory lesion types, with full resolution (ANdT=0) achieved in up to 20% of patients. Additionally, clinically meaningful improvements in quality-of-life measures, including skin pain and fatigue, were observed at Week 54. The overall safety profile of povorcitinib through 54 weeks is consistent with previously reported data, and both doses were well tolerated. Incyte (Nasdaq:INCY) to
Takeda’s Zasocitinib Delivered Rapid and Durable Skin Clearance in a Convenient Once-Daily Pill, Affirming Promise to Reshape Psoriasis Care28.3.2026 20:00:00 CET | Press release
About 70% of patients treated with zasocitinib achieved clear or almost clear skin (sPGA 0/1) at week 16 in Phase 3 plaque psoriasis studies A significantly greater PASI 75 response rate versus placebo was observed as early as week 4 Safety profile consistent with Phase 2b studies with no new safety signals identified Takeda(TSE:4502/NYSE:TAK)today announced new data from the two pivotal Phase 3studies of zasocitinib (TAK-279), a next-generation, highly selective oral tyrosine kinase 2 (TYK2) inhibitor, in adults with moderate-to-severe plaque psoriasis (PsO).1 Presented as a late-breaking abstract at the 2026 American Academy of Dermatology (AAD) Annual Meeting, these data show that convenient once-daily oral zasocitinib demonstrated rapid and durable skin clearance with a safety profile consistent with Phase 2b studies.1,2 “Our goal in psoriasis treatment is clear or almost clear skin, and previously this has been achieved primarily with injectable therapies,” said Melinda Gooderham,
AAD 2026: Late-Breaking Nemolizumab Data Demonstrate Clinically Meaningful Benefits for Children Aged 2 to 11 With Moderate-to-Severe Atopic Dermatitis28.3.2026 16:00:00 CET | Press release
Pharmacokinetics, safety and efficacy clinical study data show that nemolizumab achieved clinically meaningful reductions in skin lesions and itch through Week 16, which were sustained up to a year in children aged 2 to 11 with moderate-to-severe atopic dermatitis1 These findings reinforce the previously established safety and efficacy of nemolizumab in adults and adolescents with moderate-to-severe atopic dermatitis, for which it is approved by multiple global regulatory authorities2,3 Up to 25% of children are affected by atopic dermatitis, and currently there are limited approved treatment options for children living with moderate-to-severe atopic dermatitis4,5 Galderma (SIX: GALD) today announced new phase II data showing that nemolizumab was well tolerated and effective in children (aged 2 to 11 years) with moderate-to-severe atopic dermatitis, with a clinically meaningful and sustained reduction in skin lesions and itch for up to a year.1 Results will be presented in a late-break
Angelalign Technology (6699.HK)Releases 2025 Results: Passion for Clinical Excellence Drives Worldwide Growth27.3.2026 20:56:00 CET | Press release
Angelalign Technology Inc. (6699.HK) (“Angel” or the “Company”) released its financial results for fiscal year 2025. During the reporting period, the Company continued to do well in both the global and China markets. Total case volume was 532,400, which increased 48.1%, revenue was USD 370.3 million, which increased 37.8%, and adjusted net profit was USD 43.8 million, which increased 63.0%. The results were driven by Angel’s passion for clinical excellence and its open and inclusive culture that empowers talented people to work together to meet customer needs, the Company said. Fox Hu, CEO of Angel, stated: “The clear aligner industry is complex and multidisciplinary. It requires top-tier technical and operational talent along with seamless collaboration among professionals from diverse geographies. Angel’s open and inclusive culture attracts professionals who share a passion for clinical excellence and a dedication to bringing outstanding products and services to customers. This melti
Axway Positioned as a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment27.3.2026 18:46:00 CET | Press release
Axway, a 74Software company (Euronext: 74SW) and global leader in federated API management and enterprise integration, has been named a Leader in the IDC MarketScape: Worldwide API Management 2026 Vendor Assessment.1 Axway Amplify securely connects, orchestrates, and automates data integration. Organizations in financial services, manufacturing, healthcare, and other industries rely on Amplify to modernize integrations and confidently unlock data to deliver superior digital services faster. The report notes: “The platform benefits from Axway’s long-standing experience in B2B integration, secure file transfer, and legacy connectivity, providing differentiated capabilities for organizations that need to expose and control APIs around core systems that are not cloud-native.”1 This multi-pattern expertise in security, integration, and federated governance — built during the early phases of the API-driven digital transformation — becomes especially critical as enterprises seek to govern dat
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom